Eμ- TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 15, 2009, Pages 6250-6255

  Gorgun, Gullu ^a   Ramsay, Alan G ^b   Holderried, Tobias A W ^a   Zahrieh, David ^a   Dieu, Rifca Le ^b   Liu, Fenglong ^a   Quackenbush, John ^a   Croce, Carlo M ^c   Gribben, John G ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; GP33 PEPTIDE; LENALIDOMIDE; PEPTIDE; PROTEIN DERIVATIVE; TCL 1 PROTEIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ONCOPROTEIN; TCL1 PROTEIN, MOUSE; THALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CHRONIC LYMPHATIC LEUKEMIA; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE COURSE; GENE CONTROL; GENE EXPRESSION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFUSION; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYNAPSE; T LYMPHOCYTE; TRANSGENIC MOUSE; ANIMAL; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOLOGICAL SYNAPSE; IMMUNOLOGY; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALIA; MUS; MUS MUSCULUS;

ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOLOGICAL SYNAPSES; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, TRANSGENIC; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; THALIDOMIDE;

EID: 65549151712     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0901166106     Document Type: Article

References (26)

1. Ramsay AG, et al. (2008) Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulat-ing drug. J Clin Invest 118:2427-2437.
2. Beyer M, et al. (2005) Reduced frequencies and suppressive function of CD4-CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 106:2018 -2025.
3. Kater AP, van Oers MH, Kipps TJ (2007) Cellular immune therapy for chronic lympho-cytic leukemia. Blood 110:2811-2818.
4. Gorgun G, et al. (2005) Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 115:1797-1805.
5. Krackhardt AM, et al. (2002) T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy. Blood 100:167-173.
6. Bichi R, et al. (2002) Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci USA 99:6955-6960.
7. Yan XJ, et al. (2006) B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci USA 103:11713-11718.
8. Tsai J, et al. (2001) RESOURCERER: a database for annotating and linking microarray resources within and across species. Genome Biol 2(11):SOFTWARE0002.
9. Lee Y, et al. (2002) Cross-referencing eukaryotic genomes: TIGR Orthologous Gene Alignments (TOGA). Genome Res 12:493-502.
10. Billadeau DD, Nolz JC, Gomez TS (2007) Regulation of T-cell activation by the cytoskel-eton. Nat Rev Immunol 7:131-143.
11. Kane LP, et al. (2001) Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol 2:37-44.
12. Coyle AJ, Gutierrez-Ramos JC (2001) The expanding B7 superfamily: increasing complexity in costimulatory signals regulating T cell function. Nat Immunol 2:203-209.
13. Holdorf AD, et al. (2002) Regulation of Lck activity by CD4 and CD28 in the immunological synapse. Nat Immunol 3:259-264.
14. Faccio R, et al. (2005) Vav3 regulates osteoclast function and bone mass. Nat Med 11:284-290.
15. Wulfing C, et al. (2002) Costimulation and endogenous MHC ligands contribute to T cell recognition. Nat Immunol 3:42-47.
16. Buhmann R, et al. (1999) CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood 93:1992-2002.
17. Chanan-Khan A, et al. (2006) Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol 24:5343-5349.
18. Ferrajoli A, et al. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291-5297.
19. Andritsos LA, et al. (2008) Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lympho-cytic leukemia. J Clin Oncol 26:2519-2525.
20. Johnson AJ, et al. (2006) Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood 108:1334-1338.
21. Li C, Wong WH (2001) Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 98:31-36.
22. Mutter GL, et al. (2001) Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. Gynecol Oncol 83:177-185.
23. Doniger SW, et al. (2003) MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol (1)R7:1-12.
24. Trojan A, et al. (2000) Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies. Nat Med 6:667-672.
25. Aichele P, et al. (1995) T cell priming versus T cell tolerance induced by synthetic peptides. J Exp Med 182:261-266.
26. Pircher H, et al. (1990) Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 346:629-633.